Dr. Davis has a 35+ year career in the discovery and development of novel therapeutics at major pharmaceutical and biotechnology companies, including the last 20 years at Johnson & Johnson.
Hugh was the VP and Head of the Biologics Development Sciences department in Janssen Biotherapeutics (JBIO), leading a group of up to 200+ scientists in the biophysical characterization of discovery assets. In addition, over the last 5-6 years in JBIO at J&J, Hugh was also the China Biologics Leader. Together with his team, Dr. Davis was instrumental in the development and approval of many biologic therapies at J&J . Following his tenure at J&J, Dr. Davis took the role of Chief Business Officer at Frontage Laboratories, leading the company to a very successful IPO, on the Hong Kong Exchange (HKSE: 1521) .
Dr. Davis holds a Ph.D. degree in Biochemistry from Villanova University and completed post-Doctoral training at Centocor, Inc. where he patented the characterization of the tumor biomarker for ovarian cancer, CA125.